Representative Carol Spackman Moss proposes the following substitute bill:

**COVERAGE FOR EOSINOPHILIC DISORDERS**

2015 GENERAL SESSION
STATE OF UTAH

Chief Sponsor: Carol Spackman Moss
Senate Sponsor: ___________

---

**LONG TITLE**

**General Description:**

This bill amends the Insurance Code to require health insurance coverage for the use of an amino acid-based elemental formula, regardless of the delivery method of the formula, for the diagnosis or treatment of an eosinophilic gastrointestinal disorder.

**Highlighted Provisions:**

This bill:
- defines terms;
- requires a health benefit plan effective or renewed on or after January 1, 2017, to provide coverage for the use of an amino acid-based elemental formula, regardless of the delivery method of the formula, for the diagnosis or treatment of an eosinophilic gastrointestinal disorder;
- grants administrative rulemaking authority to the insurance commissioner; and
- provides that exemptions to insurance coverage mandates for health benefit plans do not apply to the insurance coverage for the use of an amino acid-based formula for the diagnosis or treatment of an eosinophilic gastrointestinal disorder.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**
Be it enacted by the Legislature of the state of Utah:

Section 1. Section 31A-22-644 is enacted to read:

31A-22-644. Insurance coverage for amino acid-based formula.

(1) As used in this section:
   (a) "Amino acid-based elemental formula" means a nutrition formula:
      (i) made from individual non-allergenic amino acids that are broken down to enhance
      absorption and digestion; and
      (ii) designed for individuals who have a dysfunctional gastrointestinal tract and are
      unable to tolerate and absorb whole foods or formulas composed of whole proteins, fats, or
      carbohydrates.
   (b) (i) "Eosinophilic gastrointestinal disorder" means a disorder characterized by
      having above normal amounts of eosinophils in one or more specific places anywhere in the
      digestive system.
      (ii) "Eosinophilic gastrointestinal disorder" includes:
         (A) eosinophilic esophagitis;
         (B) eosinophilic gastritis;
         (C) eosinophilic gastroenteritis;
         (D) eosinophilic enteritis; and
         (E) eosinophilic colitis.

(2) Notwithstanding Subsection 31A-22-618.5(2)(b)(i)(D), a health benefit plan
    effective or renewed on or after January 1, 2017, shall provide coverage for the use of an amino
    acid-based elemental formula, regardless of the delivery method of the formula, for the
    diagnosis or treatment of an eosinophilic gastrointestinal disorder if prescribed by a physician
    licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Chapter 68, Utah
    Osteopathic Medical Practice Act, and if dispensed by a pharmacy licensed under Title 58,
    Chapter 17b, Utah Pharmacy Practice Act.
(3) The commissioner shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, that set minimum standards for the coverage described in Subsection (2).